3980 PREMIER DR, HIGH POINT, NC
vTv Therapeutics Inc. Adopts Third Amended and Restated By-Laws
Reports Second Quarter 2026 Financial Results and Provides Corporate Update
vTv Therapeutics Inc. Elects Board Members at 2026 Annual Meeting
vTv Therapeutics Inc. Increases Class A Common Stock Offering Under ATM Program
Investor Presentation
Financial Results, Press Release
vTv Therapeutics Enters Second Amendment with Newsoara for PDE4 Inhibitor
Q2
Q1
FY 2025
Q3
FY 2024
Prospectus Filed Pursuant to Rule 424(b)(2)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
Definitive Information Statement
Preliminary Information Statement
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload
Confidential Treatment Order